Frequently asked questions

Find answers to our most frequently asked questions. If you still need help, then speak to us.






























General information

Where does Medicines Discovery Catapult fit in?

Medicines Discovery Catapult works at the frontier of drug discovery. It is a national Life Sciences service, ensuring that every move counts for innovators as they carry out their research. Medicines Discovery Catapult’s approach to drug discovery drives game-changing breakthroughs and improves patients’ lives. 

To find out how we can support your drug discovery project, speak to us

What issues are drug discovery innovators facing?

Drug discovery is high-risk and there can be much at stake – technically, financially, and reputationally.  

Innovators may: 

  • Lack the funding to do critical research or not have the data to secure the next level of funding.  
  • Have limited access to the right technology and need help to understand the unmet patient needs or the market opportunity.  
  • Need help to navigate the expertise, resources and skills within the complex Life Science ecosystem.  
  • Not always know the best, most effective, and most efficient way forward.  

For help navigating your drug discovery project, speak to us

Why should innovators work with Medicines Discovery Catapult?

Medicines Discovery Catapult is a national Life Sciences service, de-risking investment and driving impact. When the stakes are this high, we help make sure the next move counts. Using our expertise, data, insights, and technology, we unlock data to validate new ideas and identify the fastest, safest route to accelerate commercial success. 

We create momentum by mobilising the right people and partnerships. Where there is unmet patient need, we stimulate innovation through its National Programmes. This approach to drug discovery drives game-changing breakthroughs and improves patients’ lives. 

To partner or collaborate with Medicines Discovery Catapult, please speak to us

What impact has Medicines Discovery Catapult had?

Medicines Discovery Catapult has supported 389 SMEs on their journey to commercial success and helped them generate over £1.8bn of R&D investment. Its support has helped partners move five new drugs to clinical trials.  

  • Where there is unmet patient need, we have stimulated innovation through our National Programmes.  
  • In our role as a national Life Sciences service, Medicines Discovery Catapult uncovers and shares industry-leading insights that inform drug discovery.  
  • We feed innovation back into the sector to transform the way research is conducted. 
  • Medicines Discovery Catapult’s approach to drug discovery drives game-changing breakthroughs and improves patients’ lives. 

Find out more about our impact. 

What support does Medicines Discovery Catapult offer?

Our exceptional people help make the next move count for innovators on the brink of discovery. Our teams have deep scientific expertise and access to the very best technology. When combined with the latest market insights and business intelligence, our support gives innovators the best chance of commercial success. 

Partner with our experts to accelerate your drug discovery project. 

How does Medicines Discovery Catapult help innovators?

Medicines Discovery Catapult is a national Life Sciences service, de-risking investment and driving impact. We unlock data to validate a new idea and build long-term success, giving innovators the support and momentum they need to get there. We ask the right questions at the right time, to make sure every move counts.  

Much of our expertise lies in our own teams and technology, but we also have a network of funders, investors, academics, pharma and patient communities across the sector.  

Partner with our experts to accelerate your drug discovery project. 

What does Medicines Discovery Catapult do in drug discovery?

    Medicines Discovery Catapult creates long-term impact. We work closely with scientists from across the sector to set the most effective strategic roadmap for success. We create momentum through our unique blend of discovery expertise, technology, insights, and sector-leading partnerships.  

    Where there is unmet patient need, we stimulate innovation through our National Programmes. Our approach to drug discovery drives game-changing breakthroughs and improves patients’ lives. 

    Partner with our experts to accelerate your drug discovery project. 

    How does Medicines Discovery Catapult support drug discovery?

    Drug discovery is hard, and the stakes are high. We minimise risk and delay. As a national Life Sciences service, we give innovators access to the country’s best experts equipped with industry-leading technology and commercial insights. By asking the right questions at the right time, we help entrepreneurial scientists validate their ideas and make sure the next move counts.  

    Partner with our experts to accelerate your drug discovery project. 

    Why does Medicines Discovery Catapult exist?

    Medicines Discovery Catapult exists to improve lives. Medicines Discovery Catapult works at the frontier of drug discovery, helping entrepreneurs make game-changing breakthroughs to solve challenging unmet patient needs. We help improve people’s lives, increase the impact of the Life Sciences sector, and improve the health of our society and economy. 

    Partner with our experts to accelerate your drug discovery project. 

    Where is Medicines Discovery Catapult located?

    Medicines Discovery Catapult are headquartered at Alderley Park in Cheshire, which is the UK’s second-largest life sciences cluster. Our facility includes specialised laboratories for radiochemistry, mass spectrometry, and advanced imaging. 

    If you would like to use our facilities to aid in your research, then please speak to us with details of your requirements to see if we can help. 

    What are Medicines Discovery Catapult’s core therapeutic areas of expertise?

    Medicines Discovery Catapult provides specialised support across all areas of drug discovery and also focuses on four key therapeutic areas: 

    • Neuroscience: Integrated platforms for neurological, neurodegenerative, and psychiatric conditions. 
    • Oncology: Supporting target validation and early development through clinical strategy. 
    • Immunology: Developing disease-relevant in vitro models and interrogating immune responses. 
    • Infectious Disease: Strategic and hands-on support for bacterial, viral, or fungal pathogen research. 

    Speak to us to find out how we can support your specialist project. 

    Who does Medicines Discovery Catapult work with?

    Medicines Discovery Catapult works with and connects the entire Life Sciences sector. This includes: 

    • SME Therapeutic Developers and Biotech Companies. 
    • Technology Innovators and Academics. 
    • Large Pharmaceutical companies and Medical Research Charities. 

    Partner with our experts to accelerate your drug discovery project. 

    What is Medicines Discovery Catapult?

    Medicines Discovery Catapult is a national Life Sciences service in the UK dedicated to driving game-changing breakthroughs in medicine to improve patient lives. As part of the Innovate UK Catapult network, it functions to de-risk new medicines discovery by providing access to advanced technologies, specialised skills, and deep industry knowledge. 

    To find out how we can support your drug discovery project, speak to us.  

    Services and capabilities

    What are Medicines Discovery Catapult’s National Programmes?

    Our National Programmes have been created to tackle these most pressing global health challenges and include: 

    • CF AMR Syndicate –  Creating a platform for next-generation diagnostics and therapies in chronic respiratory infections—tailored to the needs of patients with CF and broader lung conditions. 
    • NPIP – The UK’s first-of-its-kind national total-body PET imaging platform for drug discovery research. 
    • PACE – Driving the development of new tests and treatments to tackle deadly antimicrobial resistance. 
    • Psychiatry Consortium –  Identifying and validating novel drug targets to address the unmet therapeutic needs of the people living with mental health conditions. 

    If you would like to discuss innovative research in relation to our National Programmes, please speak to us

    Which global health challenges are Medicines Discovery Catapult tackling?

    Medicines Discovery Catapult leads several large-scale national initiatives designed to address major global health challenges where the commercial market may be struggling. Current focus areas include: 

    • Total-body PET: Highly sensitive dynamic imaging of the whole human body, whilst reducing radiation exposure. 
    • Mental Health: A global collaboration to accelerate drug discovery for mental health. 

    If you would like to discuss innovative research in relation to major global health challenges, please speak to us. 

    What is your total-body PET capability?

    National program, NPIP, is the National PET Imaging Network. This total-body PET imaging allows for the simultaneous scanning of all organs in the body, providing unprecedented data on drug distribution, kinetics, and multi-organ interaction in real-time. 

    If you are interested in finding out more about total-body PET technology, then please speak to the team at NPIP

    What technology platforms are available?

    Medicines Discovery Catapult provides access to a wide range of advanced technology platforms, including: 

    • Mass Spectrometry – Our Mass Spectrometry team guides you through complex methods and platforms, supporting your project from discovery to clinical development. 
    • Special Biology – We offer Spatial Biology solutions that deliver high-resolution, biologically contextualised data to support informed decisions across therapeutic areas. 
    • Microscopy – From Target Engagement to Biomarker Validation, our Microscopy solutions connect cellular insights to translational outcomes. 
    • Preclinical Imaging – We offer in vivo imaging solutions that deliver high-quality data and actionable insights to support decisions across therapeutic areas. 
    • Chemical Protein Stability Assay (CPSA) – Our patented assay applies to a range of cellular protein targets and can be configured using a range of protein detection technologies, depending on the throughput required for analysis. 

    If you would benefit from use of our platforms, then please get in touch

    How does Medicines Discovery Catapult support the drug discovery process?

    Medicines Discovery Catapult aligns its services with the entire drug discovery pipeline, from target selection and hit identification, to pre-clinical models and preparation for clinical trials. We provide R&D consultancy to help partners to make their next move count, developing roadmaps for getting drugs to market. 

    Find out if we can aid you through the drug discovery process – speak to us. 

    What specific capabilities does Medicines Discovery Catapult offer?

    Medicines Discovery Catapult excels in three core pillars of Drug Discovery: 

    • In vitro Biology: Focuses on understanding cell biology, modelling disease to mimic real-world conditions, and analysing drug-target interactions. 
    • In vivo Biology: Utilises state-of-the-art non-invasive imaging technologies to understand drug distribution and efficacy. 
    • Translational Medicine: Provides biomarker analysis and data-driven insights to help transform molecules into medicines. 

    To make your next move count, then speak to us

    Working with Medicines Discovery Catapult

    Does Medicines Discovery Catapult offer consultancy services?

    Yes, Medicines Discovery Catapult provides R&D consultancy. Our work spans traditional small molecules, biologics (including oligonucleotide and antibody therapeutics), and nanoparticle delivery systems. 

    We understand how to get a drug to market and work with you to develop a plan to make your next move count.  We apply scientific understanding to unmet patient needs, identifying the most effective way to develop new medicines. 

    For R&D consultancy, please head to the linked web page and complete the form within the page to see how we can help advance your drug discovery project. 

    Can Medicines Discovery Catapult help with clinical study design?

    Yes, Medicines Discovery Catapult’s Translational Medicine team supports early-phase clinical study design by developing bespoke biomarker solutions, validating diagnostic tools, and providing access to high-quality clinical samples. 

    For support with your clinical study, please speak to us

    How does Medicines Discovery Catapult help de-risk drug development?

    Our exerts and state of the art facilities are equipped to de-risk drug development projects at every stage of the journey. 

    One such example, is by using human-relevant disease models (such as iPSCs and primary cells) and advanced biomarker strategies, can identify and mitigate potential failure points early in the development process. 

    For help de-risking your project, please speak to us. 

    Partnerships and collaboration models

    When should I contact you to act as a collaborative partner on grant bids?

    To be considered as a collaborative partner on grant bids, please reach out as early as possible once a funding call is live. Please reach out as early as possible once a funding call is live. We typically cannot support bids submitted with fewer than three weeks’ notice. 

    Partner with our experts to accelerate your drug discovery project. 

    Do you write grant applications?

    We do not offer standalone grant writing services, but when we partner on a bid, we contribute to content and review. 

    Partner with our experts to accelerate your drug discovery project. 

    Does Medicines Discovery Catapult provide direct funding or grants?

    No, Medicines Discovery Catapult does not provide direct financial grants. However, we help select partners secure funding by acting as a collaborative partner on grant bids, providing technical validation. 

    To be considered as a collaborative grant partner, please reach out as early as possible once a funding call is live. We typically cannot support bids submitted with fewer than three weeks’ notice. 

    Partner with our experts to accelerate your drug discovery project.  

    How can I work with Medicines Discovery Catapult?

    There are several ways to engage with us depending on your project’s needs: 

    • Fee-for-Service: Direct access to our state-of-the-art labs and expertise for specific experiments. 
    • Collaborative R&D: Jointly applied for grant funding (e.g., Innovate UK, MRC) where Medicines Discovery Catapult acts as a Research and Technology Organisation (RTO). 
    • Knowledge Transfer Partnerships (KTPs): Medicines Discovery Catapult is a certified “Knowledge Base,” allowing businesses to embed new drug discovery capabilities through high-calibre graduates (KTP Associates). 
    • Strategic Alliances: Deep, long-term partnerships to tackle industry-wide challenges or develop new technology platforms. 

    Speak to us to find out how we can best help get your research off the ground.  

    Supporting your drug discovery

    Is my drug discovery project commercially viable?

    Whether your project is academic or pre-commercial, we can help support you in driving it towards commercialisation. We can offer guidance on your future customers’ needs, honing your plans and your data package to maximise their coherence and credibility, helping you make your project more attractive to investors. 

    Partner with our experts to understand the commercial viability of your drug discovery project. 

    What is needed to establish a drug discovery data package that will be credible to investors, pharma and regulators?

    With our extensive discovery experience, we can advise on what is needed to progress your molecule and we can help you to develop and implement a strategy to generate this data and understanding. 

    Partner with our experts to accelerate your drug discovery project. 

    How can I predict the efficacy and safety of my molecule in a pre-clinical setting?

    We can help you evaluate your lead molecule in cutting edge in vitro and in vivo human cell models to build confidence in your asset as you progress towards the clinic. 

    Partner with our experts to accelerate your drug discovery project. 

    Does my compound bind to its target and can I measure the expected cellular effect?

    We can deploy our suite of analytical technologies to build a platform of evidence connecting your drug, its biological target, and downstream effects. These assays can then be deployed to support project progression. 

    Partner with our experts to accelerate your drug discovery project. 

    What is the biodistribution of my drug molecule or drug delivery technology?

    We can use our advanced technologies to measure the distribution of your drug molecule or drug delivery technology in vivo to demonstrate that it reaches its target tissue, then delve deeper to measure the distribution of the drug molecule within the tissue and its downstream effects. 

    Partner with our experts to accelerate your drug discovery project. 

    How can I establish a translational biomarker for my drug programme?

    We can help you identify and measure translatable biomarkers that can be applied to demonstrate that your drug is exhibiting its desired effect at each stage of your project journey and help to understand which patients could benefit from your drug. 

    Work with us to evolve your biomarker strategy. 

    Can you help me validate my technology?

    We are committed to supporting the progression of new technologies and approaches that are relevant to drug discovery. Whether a novel method or a new technology, we can help you validate and benchmark your platform in a drug discovery environment and develop new applications that can grow your business. 

    Speak with our team today to explore how we can support your research.   

    How can I boost my drug discovery project’s chance of success?

    We use predictive models and data-driven analytics to predict druggability from a raw dataset or a candidate list of targets, and then select the most likely successful therapeutic modality class for these. Thereby mitigating risks; saving time and money; streamlining decision-making; increasing the chances of success and getting your drug to market quicker. 

    Make your next move count – speak to us

    How efficacious and safe is my drug likely to be?

    Our predictive models and data-driven analytics can go a long way to detailing the efficacy and safety of a new medicine, before a single test on animal or human takes place. 

    For help de-risking your project, please speak to us

    Can my drug be repurposed?

    Finding an alternative use – or uses – for an existing medicine can be hugely beneficial. With its testing and safety compliance already in place, a drug can be sped to market at minimum cost. By cross-referencing a drug’s composition and effects with very large amounts of research data, new opportunities can present themselves. 

    Partner with our experts to accelerate your drug repurposing project. 

    Could my drug be used in combination with others?

    People suffering from complex or multifaceted issues often benefit from combinations of drugs, which can work to increase efficacy, overcome resistance and reduce adverse reactions. Through the close analysis of extremely large amounts of data, we can find opportunities for your drug to work in harmony with others. 

    Partner with our experts to accelerate your drug discovery project. 

    How can I find lead compounds faster?

    Chemical space is vast, and only a fraction of it has been explored in terms of drug discovery. Through virtual screening and in-depth analysis of bioactivities, we can support in identifying potential lead compounds for you, at speed and with confidence. 

    Partner with our experts to accelerate your drug discovery project. 

    Commercial

    What does it mean to be “Fit to Fund”?

    Many early-stage biotechs have great science but lack the industrial-grade data required by investors. Medicines Discovery Catapult helps “de-risk” these companies by validating their science using industry-standard assays and providing the robust data packages that venture capitalists and big pharma look for during due diligence. 

    Partner with us to de-risk your drug discovery project. 

    Is Medicines Discovery Catapult a government agency?

    Medicines Discovery Catapult is an independent, not-for-profit company. We are part of the Innovate UK Catapult Network and receive core funding from Innovate UK (part of UK Research and Innovation), but we operate with a commercial mindset to serve the life sciences industry. 

    Partner with us to accelerate your drug discovery project. 

    In vitro biology capabilities

    What advanced phenotypic analysis techniques are available?

    Medicines Discovery Catapult employs high-resolution microscopy and phenotypic assays tailored to specific disease biology to evaluate how therapeutics interact with targets. 

    We use back-translation techniques, taking data from clinical samples to build and validate superior in vitro models. 

    Speak with our team today to explore how we can support your in vitro biology research.   

    Can you help me validate my technology?

    We are committed to supporting the progression of new technologies and approaches that are relevant to drug discovery. Whether a novel method or a new technology, we can help you validate and benchmark your platform in a drug discovery environment and develop new applications that can grow your business. 

    Speak with our team today to explore how we can support your research.   

    In vivo biology and imaging

    What are the benefits of Spatial Mass Spectrometry Imaging?

    This is a label-free technique that allows for the simultaneous acquisition of hundreds of molecules from a single tissue experiment. 

    It integrates drug biodistribution with biomarker imaging, showing exactly where a drug locates within a structure (e.g. distinguishing between grey and white matter in the brain). 

    Speak with our team today to explore how we can support your in vivo biology research. 

    Can Medicines Discovery Catapult assist with targeted radiotherapy and radiopharmaceutical development?

    Yes, Medicines Discovery Catapult has a dedicated radiochemistry capability with an established supply of various radioisotopes, including 225Ac, 177Lu, 89Zr, 68Ga, and 18F. 

    Services include the modification of proteins with bifunctional radiometal chelators and the radiolabelling of small molecules, peptides, and biologics. 

    Medicines Discovery Catapult also provides a Preclinical Radiotherapy Platform and expertise in evaluating the stability and biodistribution of radioligands. 

    Speak with our team today to explore how we can support your in vivo biology research. 

    What specific non-invasive imaging modalities can be used for drug distribution studies?

    The state-of-the-art suite includes Positron Emission Tomography (PET), Computed Tomography (CT), and High-Frequency Ultrasound (HFUS). 

    We also offer Bioluminescence and near-Infrared imaging (IVIS) for monitoring treatment response and tumour growth in real-time. 

    Speak with our team today to explore how we can support your in vivo biology research.   

    Translational medicine and biomarkers

    Are Medicines Discovery Catapult’s laboratory services safe?

    Medicines Discovery Catapult goes to extra lengths to ensure safety and is certified ISO 45001. The ISO 45001 standard is the world’s first international standard for occupational health and safety. Independently certified, it provides a framework to increase safety, reduce workplace risks and enhance health and wellbeing in the workplace. 

    Make your next move count. Speak to us to safely advance your drug discovery project.  

    Are Medicines Discovery Catapult’s laboratory services compliant with clinical standards?

    Yes, Medicines Discovery Catapult can run developed and validated assays to Good Clinical Laboratory Practice (GCLP) standards. 

    This ensures that the data generated is robust enough to inform critical clinical decisions, such as dosing strategies and patient selection. 

    Medicines Discovery Catapult is also ISO 45001 certified. The ISO 45001 standard is the world’s first international standard for occupational health and safety. Independently certified, it provides a framework to increase safety, reduce workplace risks and enhance health and wellbeing in the workplace. 

    Need support in developing your drug for clinical trials? Speak to us to see how we can advance your drug discovery project.  

    What “Omic” platforms are available for biomarker discovery?

    Medicines Discovery Catapult offers an extensive range of multi-omic profiling, including Transcriptomics, Proteomics, Metabolomics, and Lipidomics. 

    We specialise in Spatial Biology to map target expression across various tumour types and identify specific cell types involved in disease progression. 

    Work with us to evolve your biomarker strategy. 

    How does Medicines Discovery Catapult support patient stratification in early-phase trials?

    Medicines Discovery Catapult develops bespoke biomarker strategies and assays, such as multiplexed circulating tumour DNA (ctDNA) assays. For example, we have verified assays that can detect 14 different KRAS and BRAF mutations from liquid biopsies using droplet digital PCR (ddPCR), which is sensitive enough to detect single copies of a mutation. 

    Work with us to establish your patient stratification. 







    Partner with us and make sure your next move counts

    See how we can help support you with your next drug discovery project.

    Speak to us



    Medicines Discovery Catapult